NovaBay®
Pharmaceuticals, Inc. NBY, a biotechnology company focused on
addressing the large unmet therapeutic needs of the global anti-infective
market with first-in-class compounds such as its proprietary Aganocides®,
today announced that the World Health Organization (WHO) has approved the
international nonproprietary name (INN) "auriclosene" (pronounced
awr-rih-CLO-zeen) for the Company's lead Aganocide® compound NVC-422. INNs
facilitate the identification of active pharmaceutical ingredients, and each
INN is a globally recognized unique name.
Aganocides are NovaBay's first-in-class topical antimicrobial compounds, which
are active against viruses, fungi, and bacteria, including the bacteria that
grow and thrive under biofilm. Testing in-vitro and in-vivo has shown that
these non-systemic, non-antibiotic compounds do not give rise to bacterial or
fungal resistance. Phase 2 studies for auriclosene are currently ongoing in
urology, ophthalmology, and dermatology.
Dr. Ron Najafi, Chairman and Chief Executive Officer, said, "Obtaining the INN
for our lead clinical compound NVC-422 confirms that our clinical development
is on track, and we anticipate progression into Phase 3 development in each of
our three Aganocide programs. We also intend to conduct a Phase 2a
proof-of-concept study for auriclosene in an additional ophthalmic indication.
NVC-422, now auriclosene, is the first of our proprietary Aganocides to
receive a nonproprietary name."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in